Thymosin Alpha-1: Scientific Profile

Publicado el 12 de julio de 2026 · Actualizado el 24 de agosto de 2026

Thymosin Alpha-1 (Thymalfasin, TA1; CAS 62304-98-7) is a 28-amino-acid immunomodulatory peptide derived from thymosin fraction 5 of the thymus. In research it is studied for its ability to reorient the maturation of T lymphocytes and modulate the innate and adaptive immune response through Toll-like receptors. Material for research use.

Thymosin Alpha-1, also known as thymalfasin or TA1, is a 28-amino-acid peptide with molecular formula C129H215N33O55 and a molecular weight of 3108.32 g/mol (CAS 62304-98-7). It corresponds to a fragment acetylated at its N-terminus that was originally isolated from thymosin fraction 5, a protein preparation obtained from bovine thymus described by Allan Goldstein and colleagues in the 1970s. It was identified as one of the most active components of that fraction in restoring immunological functions, and today it is produced by chemical synthesis or by the recombinant route for research use. It belongs to the family of beta-thymosins and alpha-thymosins associated with the biology of the thymus, the central organ of T-lymphocyte maturation.

Structurally, Thymosin Alpha-1 is a small, highly acidic peptide without disulfide bridges, whose sequence begins with an N-acetylated serine. In aqueous solution it behaves as a predominantly disordered peptide that can adopt partial secondary structure (helical regions and turns) upon interacting with membranes or protein surfaces. This conformational plasticity is consistent with its proposed role as a signaling peptide and modulator of protein-protein interactions rather than as a molecule with a defined catalytic site.

The investigated mechanism of action of Thymosin Alpha-1 is pleiotropic and centers on the modulation of immunity. In preclinical models and cellular studies it has been described that TA1 acts on the maturation and differentiation of thymocytes into functional T lymphocytes, favoring helper T cell populations. At the molecular level, much of its activity has been attributed to signaling through Toll-like receptors, in particular TLR2 and TLR9, with downstream activation of the MyD88 pathway and the transcription factor NF-κB in dendritic cells and monocytes. This translates, in the studied models, into a modulation of cytokine production —including interferons and interleukins associated with Th1 responses— and an increase in natural killer cell activity. Its influence on the balance between proinflammatory and regulatory responses, as well as on the expression of major histocompatibility complex molecules, has also been explored. Overall, the predominant mechanistic reading is that of a peptide that "resets" or redirects a dysregulated immune response, rather than a unidirectional immunostimulant or immunosuppressant.

The documented research applications of Thymosin Alpha-1 are considerably more robust than those of most catalog peptides, since a body of real clinical literature exists. Under the name thymalfasin (marketed as Zadaxin in several countries, although it does not have FDA approval in the United States), it has been widely investigated as an adjuvant agent. The best-characterized lines of study include chronic infection by hepatitis B virus and hepatitis C, where it has been evaluated alone and in combination with interferon and antivirals; the potentiation of the response to vaccines in populations with compromised immunity, such as elderly patients or those on hemodialysis; and adjuvant use in oncology, exploring its role alongside chemotherapy in various solid tumors. A more recent and much-discussed chapter was its evaluation in sepsis and in severe illness associated with respiratory infections, contexts in which interest focused on its capacity to counteract immune anergy and lymphopenia. It is important to frame all of these findings as objects of study: the methodological quality of the trials is heterogeneous, many come from a limited number of groups or regions, and systematic reviews have pointed to both promising signals and the need for controlled trials of greater size and rigor.

As for the level of evidence, Thymosin Alpha-1 occupies a favorable position within the universe of research peptides: it is a chemically well-characterized molecule, with decades of study, with regulatory approval in several countries outside the United States, and with published clinical trials in humans. For this reason its evidence is classified as clinical-level. Nevertheless, this classification should not be read as an assertion of established and universal efficacy: for several of the explored indications the results remain a subject of debate, the magnitude of the benefit is variable, and it has not been adopted as a standard of treatment in most health systems. Its safety profile reported in the literature has been generally favorable, with good local and systemic tolerance in the studies, which has facilitated its investigation in fragile populations.

For the researcher, Thymosin Alpha-1 constitutes a tool for probing the interface between innate and adaptive immunity, useful in models of immunomodulation, TLR signaling, dendritic cell biology, and antiviral or vaccine responses. Its nature as a short, hydrophilic peptide without especially labile residues facilitates its experimental handling, although, like any peptide, it requires control of reconstitution, pH, and temperature to preserve its integrity.